BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Reata Pharmaceuticals, Inc. Adding Jobs, Stays in Dallas Because of Abbott Laboratories (ABT) Deal


10/4/2010 8:25:58 AM

Dallas Business Journal - by Bill Hethcock Staff Writer -- An $800 million deal between North Texas drug development firm Reata Pharmaceuticals Inc. and Illinois-based Abbott Laboratories will create up to 100 new jobs and could eventually position the region as a biopharmaceutical hub, Reata’s chief executive said this week.

Warren Huff, CEO of Irving-based Reata, said the company has doubled to 100 employees since January, and plans to add 50 to 100 more over the next 12 to 18 months to complete development and prepare for the launch of bardoxolone, the firm’s drug for chronic kidney disease.

Reata recently added more than 20,000 square feet at its Gateway Drive headquarters in Irving to prepare for the growth, taking its total space to about 40,000 square feet, Huff said.

Reata announced Sept. 23 that the firm reached an agreement with Abbott Park, Ill.-based Abbott Laboratories that includes a $450 million cash payment to Reata plus $350 million in milestone payments as drug development progresses. Abbott took a minority stake of an undisclosed size in Reata as part of the deal. The agreement gives Abbott exclusive rights to market bardoxolone outside the United States, excluding certain Asian markets.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES